Top Page
IXICO plc
(LSE:IXI)
IXICO plc (IXI) vs. iShares MSCI United Kingdom ETF (EWC)
IXICO plc Business Overview & Revenue Model
IXICO plc Financial Statement Overview
| Breakdown | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.77M | 6.67M | 8.64M | 9.19M | 9.53M |
| Gross Profit | 2.71M | 3.27M | 4.77M | 5.53M | 5.91M |
| EBITDA | -1.95M | -707.00K | 750.00K | 1.31M | 674.00K |
| Net Income | -2.00M | -1.18M | 1.03M | 1.51M | 952.00K |
Balance Sheet | |||||
| Total Assets | 11.19M | 12.99M | 14.65M | 14.26M | 12.10M |
| Cash, Cash Equivalents and Short-Term Investments | 1.79M | 4.03M | 5.77M | 6.68M | 7.95M |
| Total Debt | 314.00K | 387.00K | 516.00K | 597.00K | 213.00K |
| Total Liabilities | 1.72M | 1.56M | 2.16M | 2.78M | 2.98M |
| Stockholders Equity | 9.46M | 11.43M | 12.49M | 11.48M | 9.12M |
Cash Flow | |||||
| Free Cash Flow | -2.20M | -1.66M | -815.00K | -1.54M | 795.00K |
| Operating Cash Flow | -1.73M | 302.00K | 1.43M | 614.00K | 1.94M |
| Investing Cash Flow | -377.00K | -1.86M | -2.25M | -2.15M | -1.14M |
| Financing Cash Flow | -134.00K | -156.00K | -114.00K | 270.00K | -112.00K |
IXICO plc Technical Analysis
IXICO plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | £11.35M | ― | -13.85% | ― | 7.27% | 39.64% | |
57 Neutral | £5.06B | 6.82 | -62.36% | 2.25% | 33.93% | 6.67% | |
53 Neutral | £11.75M | ― | -333.59% | ― | 45.22% | 55.71% | |
46 Neutral | £9.71M | ― | -99.43% | ― | 17.39% | 96.02% | |
44 Neutral | £11.65M | ― | -129.49% | ― | 14.12% | 78.16% |
IXICO plc Corporate Events
IXICO plc has strengthened its collaboration with the Global Alzheimer’s Platform Foundation (GAP) by securing full data usage rights for the Bio-Hermes-002 study, a significant global research initiative in Alzheimer’s Disease (AD). This partnership enhances IXICO’s platform capabilities and positions it as a key player in the AD research ecosystem, allowing the company to accelerate its vascular biomarker analysis R&D program, extend its product offerings, and deepen relationships with leading biopharmaceutical companies. The agreement is expected to yield strong returns, advancing the understanding, diagnosis, and treatment of AD.
IXICO plc anticipates its revenues for the year ending 30 September 2025 to exceed expectations, reaching at least £6.3 million, marking a 9% increase from 2024. This growth is attributed to the successful implementation of its ‘Innovate Lead Scale’ strategy, which has expanded its market reach and product offerings. The company expects this positive momentum to continue into 2026, aiming for medium-term profitability, while holding at least £3.0 million in cash by the end of the financial year. The final results for the year will be announced in December 2025.
IXICO plc announced the issuance of 850,000 share options to key executives, including the Chief Technology Officer and Chief Business Officer, as part of a retention strategy linked to annual share price growth over three years. Additionally, the company’s CFO/COO, Grant Nash, conducted a share transaction involving the sale and repurchase of shares into his ISA account, maintaining his beneficial interest in the company.
IXICO has played a pivotal role in the validation of a new Alzheimer’s Disease diagnostic biomarker for Fujirebio Diagnostics, Inc., leading to the first FDA clearance of a blood-based in vitro diagnostic test for Alzheimer’s in the U.S. This milestone enhances IXICO’s capabilities in neuroimaging biomarker analyses and marks a significant advancement in early-stage Alzheimer’s diagnosis, potentially improving patient outcomes through earlier intervention.
IXICO plc has announced a notification of major holdings due to a name change of a shareholder from Amati AIM VCT plc to Maven Renovar VCT PLC, following a change in the investment manager to Maven Capital Partners UK LLP. This notification does not indicate any change in the position held by the company, serving purely as an informational update about the name change.
IXICO plc reported a 26% increase in revenue to £3.2 million for the first half of 2025, driven by diversified projects and strategic expansion in neurological disease areas. The company strengthened its operations with key hires, expanded its US footprint, and announced significant commercial partnerships, positioning itself for growth in neurodegenerative disease research.
IXICO plc announced a change in the investment manager for Amati AIM VCT plc to Maven Capital Partners UK LLP, resulting in a name change to Maven Renovar VCT plc. Despite this change, there has been no alteration in the position held in IXICO, indicating stability in the company’s shareholder structure. This announcement reflects IXICO’s ongoing commitment to maintaining its operational stability and shareholder confidence, crucial for its strategic positioning in the neuroscience research industry.
IXICO plc announced it will release its unaudited interim results for the six months ending 31 March 2025 on 20 May 2025. The company will host a live presentation for shareholders to discuss these results and its ongoing strategy. This event underscores IXICO’s commitment to transparency and engagement with its stakeholders, reinforcing its position as a leader in the neuroscience imaging industry.